drugset
drugset / Trial / NCT03291041

A Proof of Concept Study to Evaluate the Effects of Tasimelteon and Placebo in Travelers With Jet Lag Disorder

NCT03291041 ↗

Phase 2 Completed 25 enrolled Vanda Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

A Proof of Concept Study to Evaluate the Effects of Tasimelteon and Placebo in Travelers With Jet Lag Disorder

Timeline

Start
2016-07
Primary completion
2017-11
Completion
2017-11

Outcome

Met primary endpoint

registry analysis (superiority test); Tasimelteon vs Placebo; p = 0.0354; Mean Difference (Net) 34.75; ANCOVA NCT03291041 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject tasimelteon Small molecule — Oral

Indications

circadian rhythm sleep disorder, jet lag type